RU2013144966A - Композиция, содержащая диаминоксидазу, для применения для лечения или предотвращения фибромиалгии или синдрома хронической усталости - Google Patents
Композиция, содержащая диаминоксидазу, для применения для лечения или предотвращения фибромиалгии или синдрома хронической усталости Download PDFInfo
- Publication number
- RU2013144966A RU2013144966A RU2013144966/15A RU2013144966A RU2013144966A RU 2013144966 A RU2013144966 A RU 2013144966A RU 2013144966/15 A RU2013144966/15 A RU 2013144966/15A RU 2013144966 A RU2013144966 A RU 2013144966A RU 2013144966 A RU2013144966 A RU 2013144966A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- dao
- powder
- administered
- diaminoxidase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 5
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims abstract 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title claims abstract 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000002502 liposome Substances 0.000 claims abstract 6
- 239000008176 lyophilized powder Substances 0.000 claims abstract 6
- 239000003094 microcapsule Substances 0.000 claims abstract 6
- 239000002088 nanocapsule Substances 0.000 claims abstract 6
- 239000000843 powder Substances 0.000 claims abstract 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960001948 caffeine Drugs 0.000 claims abstract 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002552 dosage form Substances 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 210000002784 stomach Anatomy 0.000 claims abstract 4
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03022—Diamine oxidase (1.4.3.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Применение диаминоксидазы (ДАО) для получения композиции для предотвращения или лечения фибромиалгии или синдрома хронической усталости.2. Применение по п.1, отличающееся тем, что ДАО вводят перорально в форме таблеток, капсул или саше.3. Применение по п.1, отличающееся тем, что ДАО вводят в дозе от 0,1 до 50 мг.4. Применение по п.2, отличающееся тем, что ДАО вводят в дозе от 0,1 до 50 мг.5. Применение по любому из пп.1-4, отличающееся тем, что указанная композиция дополнительно содержит кофеин.6. Применение по п.5, отличающееся тем, что кофеин вводят в дозе от 1 до 100 мг.7. Применение по любому из пп.1-4 или 6, отличающееся тем, что указанные лекарственные формы защищены от воздействия среды желудка.8. Применение по п.5, отличающееся тем, что указанные лекарственные формы защищены от воздействия среды желудка.9. Применение по любому из пп.1-4, 6 или 8, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.10. Применение по п.5, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.11. Применение по п.7, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.
Claims (11)
1. Применение диаминоксидазы (ДАО) для получения композиции для предотвращения или лечения фибромиалгии или синдрома хронической усталости.
2. Применение по п.1, отличающееся тем, что ДАО вводят перорально в форме таблеток, капсул или саше.
3. Применение по п.1, отличающееся тем, что ДАО вводят в дозе от 0,1 до 50 мг.
4. Применение по п.2, отличающееся тем, что ДАО вводят в дозе от 0,1 до 50 мг.
5. Применение по любому из пп.1-4, отличающееся тем, что указанная композиция дополнительно содержит кофеин.
6. Применение по п.5, отличающееся тем, что кофеин вводят в дозе от 1 до 100 мг.
7. Применение по любому из пп.1-4 или 6, отличающееся тем, что указанные лекарственные формы защищены от воздействия среды желудка.
8. Применение по п.5, отличающееся тем, что указанные лекарственные формы защищены от воздействия среды желудка.
9. Применение по любому из пп.1-4, 6 или 8, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.
10. Применение по п.5, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.
11. Применение по п.7, отличающееся тем, что ДАО применяют в свободной форме, в виде порошка, лиофилизированного порошка, микрокапсул, нанокапсул или липосом.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201130383 | 2011-03-18 | ||
| ES201130383A ES2388395B1 (es) | 2011-03-18 | 2011-03-18 | Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica. |
| PCT/IB2012/051276 WO2012127392A1 (en) | 2011-03-18 | 2012-03-16 | Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013144966A true RU2013144966A (ru) | 2015-04-27 |
| RU2625549C2 RU2625549C2 (ru) | 2017-07-14 |
Family
ID=45894610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013144966A RU2625549C2 (ru) | 2011-03-18 | 2012-03-16 | Композиция, содержащая диаминоксидазу, для применения для лечения или предотвращения фибромиалгии или синдрома хронической усталости |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140004179A1 (ru) |
| EP (1) | EP2686004B1 (ru) |
| CN (1) | CN103476423A (ru) |
| BR (1) | BR112013023713B1 (ru) |
| CO (1) | CO6801746A2 (ru) |
| DK (1) | DK2686004T3 (ru) |
| ES (2) | ES2388395B1 (ru) |
| HU (1) | HUE042453T2 (ru) |
| MX (1) | MX2013010695A (ru) |
| PL (1) | PL2686004T3 (ru) |
| PT (1) | PT2686004T (ru) |
| RU (1) | RU2625549C2 (ru) |
| WO (1) | WO2012127392A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2426539B1 (es) | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815177A (ru) * | 1968-10-24 | 1970-04-28 | ||
| GB1313318A (en) * | 1969-10-07 | 1973-04-11 | Urbin M C | Pharmaceutical preparation for the treatment of hemorrhoids |
| FR2101095A1 (en) * | 1970-08-20 | 1972-03-31 | Merieux Inst | Diamine oxidase from human placenta - for treatment of hyperhistamina |
| FR2215944A1 (en) * | 1973-02-01 | 1974-08-30 | Bellon Labor Sa Roger | Extracts of human placenta - free of proteases, and contg. histaminase, kininases and monoamine-oxidases for treating allergies |
| GB8319540D0 (en) * | 1983-07-20 | 1983-08-24 | Bovril Ltd | Amine removal |
| US4725540A (en) | 1984-07-09 | 1988-02-16 | Emil Underberg | Process for the preparation of amine-oxidase containing material, so produced amine-oxidase containing material |
| US7232830B2 (en) * | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| IT1317067B1 (it) | 2000-11-29 | 2003-05-26 | Univ Roma | Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico. |
| US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
| AT502098B8 (de) | 2004-07-07 | 2007-06-15 | Albert Dr Missbichler | Diaminooxidase-hältige zusammensetzung |
| AT502850B1 (de) * | 2005-11-18 | 2007-08-15 | Albert Dr Missbichler | Verfahren zur bestimmung der aktivität von diaminooxidase |
-
2011
- 2011-03-18 ES ES201130383A patent/ES2388395B1/es not_active Expired - Fee Related
-
2012
- 2012-03-16 WO PCT/IB2012/051276 patent/WO2012127392A1/en active Application Filing
- 2012-03-16 RU RU2013144966A patent/RU2625549C2/ru active
- 2012-03-16 MX MX2013010695A patent/MX2013010695A/es unknown
- 2012-03-16 CN CN2012800138576A patent/CN103476423A/zh active Pending
- 2012-03-16 HU HUE12711009A patent/HUE042453T2/hu unknown
- 2012-03-16 DK DK12711009.6T patent/DK2686004T3/en active
- 2012-03-16 ES ES12711009T patent/ES2704251T3/es active Active
- 2012-03-16 PL PL12711009T patent/PL2686004T3/pl unknown
- 2012-03-16 US US14/005,020 patent/US20140004179A1/en not_active Abandoned
- 2012-03-16 BR BR112013023713-9A patent/BR112013023713B1/pt active IP Right Grant
- 2012-03-16 EP EP12711009.6A patent/EP2686004B1/en active Active
- 2012-03-16 PT PT12711009T patent/PT2686004T/pt unknown
-
2013
- 2013-10-10 CO CO13241614A patent/CO6801746A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL2686004T3 (pl) | 2019-03-29 |
| ES2388395B1 (es) | 2013-10-01 |
| WO2012127392A1 (en) | 2012-09-27 |
| ES2388395A1 (es) | 2012-10-15 |
| EP2686004B1 (en) | 2018-09-12 |
| PT2686004T (pt) | 2018-12-18 |
| DK2686004T3 (en) | 2019-01-07 |
| CN103476423A (zh) | 2013-12-25 |
| HUE042453T2 (hu) | 2019-06-28 |
| US20140004179A1 (en) | 2014-01-02 |
| CO6801746A2 (es) | 2013-11-29 |
| BR112013023713A2 (pt) | 2016-12-13 |
| BR112013023713B1 (pt) | 2021-11-23 |
| MX2013010695A (es) | 2013-10-03 |
| ES2704251T3 (es) | 2019-03-15 |
| EP2686004A1 (en) | 2014-01-22 |
| RU2625549C2 (ru) | 2017-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012193216A5 (ru) | ||
| JP2012031147A5 (ru) | ||
| JP2010248252A5 (ru) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2016530291A5 (ru) | ||
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| RU2015147874A (ru) | Композиция, содержащая комбинацию экстракта бузины и штамма lactobacillus rhamnosus | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| JP2014527506A5 (ru) | ||
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| PH12014502836A1 (en) | Medicament form for release of active ingredients | |
| RU2013144966A (ru) | Композиция, содержащая диаминоксидазу, для применения для лечения или предотвращения фибромиалгии или синдрома хронической усталости | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| RU2013144967A (ru) | Композиции, содержащие диаминоксидазу, для предотвращения симптомов похмелья | |
| RU2012136190A (ru) | Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента | |
| RU2014140676A (ru) | Диаминоксидаза для применения в лечении или предупреждении синдрома дефицита внимания с гиперактивностью (сдвг) | |
| JP2012046484A5 (ru) |